Infinium Pharmachem receivables rise to Rs 48.50 crore in September

Infinium Pharmachem Limited reported consolidated trade receivables of Rs 48.50 crore at September 30, 2026, up from Rs 31.46 crore at March 31, 2026. Trade payables also increased, reaching Rs 21.40 crore from Rs 4.07 crore, while cash and cash equivalents stood at Rs 30.88 crore.

How much did Infinium Pharmachem’s receivables increase?

Infinium Pharmachem’s trade receivables increased by Rs 17.04 crore to Rs 48.50 crore at September 30, 2026, from Rs 31.46 crore at March 31, 2026. The receivables balance was higher than inventories of Rs 42.50 crore and cash and cash equivalents of Rs 30.88 crore at the September reporting date.

Inventories increased by Rs 3.45 crore from Rs 39.05 crore at March 31 to Rs 42.50 crore. Loans and advances declined to Rs 5.95 crore from Rs 6.84 crore, while other current assets rose to Rs 4.33 crore from Rs 2.87 crore. Total current assets consequently increased to Rs 132.37 crore from Rs 109.99 crore.

Infinium Pharmachem reported no other balances with banks at September 30, compared with Rs 26.18 crore at March 31. Cash and cash equivalents rose to Rs 30.88 crore from Rs 3.00 crore over the same balance-sheet dates, so the total of those two bank-related categories was Rs 30.88 crore at September 30 and Rs 29.18 crore at March 31.

Why did Infinium Pharmachem’s trade payables rise?

Infinium Pharmachem’s trade payables rose by Rs 17.32 crore to Rs 21.40 crore at September 30, 2026, from Rs 4.07 crore at March 31, 2026. The increase was close in absolute value to the Rs 17.04 crore rise in trade receivables, although the filing does not disclose customer or supplier terms behind either movement.

Other financial liabilities declined to Rs 7.90 crore from Rs 15.22 crore, partly offsetting the trade-payables increase within current liabilities. Other current liabilities increased to Rs 3.07 crore from Rs 2.34 crore, while provisions declined to Rs 2.93 crore from Rs 3.40 crore and income-tax liabilities fell to Rs 2.81 crore from Rs 3.64 crore.

Total current liabilities increased by Rs 13.43 crore to Rs 38.10 crore. Non-current financial liabilities rose to Rs 11.89 crore from Rs 7.64 crore, while total equity increased to Rs 149.49 crore from Rs 138.46 crore. Total assets and total equity and liabilities were each reported at Rs 199.49 crore, compared with Rs 174.94 crore at March 31.

What was Infinium Pharmachem’s operating cash flow?

Infinium Pharmachem reported net cash from operating activities of Rs 7.40 crore for the half year ended September 30, 2026, compared with Rs 2.29 crore in the half year ended September 30, 2025. Cash generated from operations was Rs 9.92 crore, versus Rs 4.09 crore a year earlier, before current tax payments of Rs 2.52 crore.

Profit before tax increased to Rs 13.01 crore for the September 2026 half year from Rs 8.33 crore in the corresponding 2025 period. Operating profit before working-capital changes was Rs 14.45 crore, compared with Rs 10.27 crore. The cash-flow statement records adjustments for operating assets and operating liabilities during the period, alongside the reported movements in receivables, inventories and payables on the balance sheet.

Investing activities used Rs 2.22 crore in the September 2026 half year, compared with Rs 1.73 crore used in the prior-year half year. Purchases of tangible fixed assets were Rs 5.43 crore, against Rs 4.86 crore in the earlier period, while the statement also showed Rs 1.77 crore of movement in other non-current assets.

Financing activities used Rs 4.08 crore in the September 2026 half year, compared with Rs 20.52 crore used in the corresponding 2025 period. The cash-flow statement reported a net increase in cash and cash equivalents of Rs 1.10 crore, against a Rs 19.95 crore decrease a year earlier, and an end-period cash and cash-equivalents balance of Rs 30.88 crore.

What do Infinium Pharmachem’s results show alongside working capital?

Infinium Pharmachem reported revenue from operations of Rs 129.72 crore for the half year ended September 30, 2026, compared with Rs 84.05 crore in the corresponding 2025 half year. Profit before tax rose to Rs 13.01 crore from Rs 8.33 crore, and the reported profit after tax before the non-controlling-interest presentation was Rs 10.45 crore, compared with Rs 6.52 crore.

Infinium Pharmachem states that it operates in one business segment, Intermediate Chemicals. Its consolidated financial statements include Shanghai Tajilin Industrial Co. Limited, Infinium Green Energy Private Limited and Infinium Healthcare Private Limited, and the balance sheet reported non-controlling interest of Rs 18.86 crore at September 30, compared with Rs 17.41 crore at March 31.

Property, plant and equipment increased to Rs 23.32 crore at September 30 from Rs 20.08 crore at March 31, while capital work in progress rose to Rs 8.88 crore from Rs 8.16 crore. Total non-current assets were Rs 67.11 crore, compared with Rs 64.92 crore six months earlier, alongside the Rs 22.38 crore increase in total current assets.

The board approved the consolidated unaudited results on November 6, 2026 after audit committee review. The independent auditor stated that nothing had come to its attention suggesting a material misstatement, while noting that interim information for one subsidiary had not been reviewed by it and had been prepared by an independent certified public accountant under International Financial Reporting Standards.

Conclusion

Infinium Pharmachem’s September 2026 disclosures show higher balances on both sides of working capital: trade receivables rose Rs 17.04 crore and trade payables rose Rs 17.32 crore from March 2026. Revenue, profit before tax and net operating cash flow were also higher than in the September 2025 half year, while total current assets increased to Rs 132.37 crore.

The next reported balance sheet will show whether trade receivables of Rs 48.50 crore and trade payables of Rs 21.40 crore decline, persist or increase further. Investors can also monitor tangible fixed-asset purchases, which were Rs 5.43 crore in the September 2026 half year, and capital work in progress of Rs 8.88 crore at the period end.